From the results of the mate analysis, the overall ORR and DCR were 20% and 60%, respectively, for PD-1/PD-L1 ICI monotherapy in liver cancer patients, while the ORR was 29% and DCR was 77% for combination therapy with anti-VEGF drugs; the overall rate of irAE was 63%, and the occurrence of severe adverse events was 11% (47). The gene discussed is CD274; the disease is liver cancer.